Other strategies targeting insulin resistance support this rationale: metformin has shown antitumor effects in preclinical models and improved outcomes in diabetic cancer patients (36, 37), whereas exogenous insulin use has been associated with a modestly increased risk of gastrointestinal tumors (38, 39). Here, INS is linked to cancer.